A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sitagliptin Combination Therapy

Inclusion Criteria:

• Patients who are diagnosed with Type2 Diabetes
• 19 ≤ Age ≤ 85
• 7.0% ≤ HbA1c ≤ 10.5%

Exclusion Criteria:

• Patients with a history of acute pancreatitis
• Patients with a history of pre-diabetic coma
• Patients with a history of diagnosis of malignant tumors within 5 years prior to visit 1